Skip to main content
Clinical Trials/NCT06378216
NCT06378216
Recruiting
Not Applicable

Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation

IRCCS Eugenio Medea1 site in 1 country30 target enrollmentSeptember 15, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myotonic Dystrophy 1
Sponsor
IRCCS Eugenio Medea
Enrollment
30
Locations
1
Primary Endpoint
cognitive evaluation by Raven Matrices
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The rationale of the study is to collect structured data in the neuropsychological, clinical neuroradiologic and neurorehabilitation fields in children/young people affected by congenital and juvenile myotonic dystrophy. Children affected by the congenital form (CDM1) present important brain alterations present since birth while, on the contrary, patients with the adult form of DM1 often present a degenerative, slowly progressive neurocognitive picture. Promising therapies that aim to correct the molecular mechanism underlying the symptoms of adult forms of DM1 are under development, but their potential role at the level of the nervous system and in particular in forms of CDM1 (which appears to be a distinct disorder of neuronal development) is also to be clarified.

To this end, a better definition of neurocognitive profiles and their evolution is essential for the purposes of evaluating the effectiveness of experimental therapies.

Detailed Description

A. Recruitment of patients with a defined diagnosis of Myotonic Dystrophy type 1 (see following inclusion and exclusion criteria) B) Clinical and cognitive evaluation 1. neurological and neuromuscular examination, compilation of the MIRS-muscle scale and EPWORTH scale-daytime sleepiness (1 session of approximately 1 hour); 2. administration of a neuropsychological battery, in order to define the level of cognitive functioning and to frame a detailed function-specific profile (multiple sessions to be defined based on the collaboration of the patients) investigating the following areas: 1. intelligence quotient; 2. attention; 3. memory; 4. visual-constructive skills and executive functions 3. psychiatric examination and administration of psychological tests (MMPI-2, Minnesota Multiphasic Personality Inventory 2) to investigate any psychopathologies (behavioral disorders, anxiety disorders, developmental disorders, hyperactivity/attention deficit) and to define the psychological-behavioral profile and adaptive (Vineland Adaptive Behavioral Scale) 4. neuroimaging examination through Morphological magnetic resonance and Diffusor Tensor imaging and Voxel Based Morphometry protocols 5. based on the clinical conditions, a cardiological evaluation will also be carried out (including instrumental tests such as Electrocardiogram ECG, echocardiogram and 24-hour ECG) and pneumological evaluation (with recording of nocturnal oximetry, spirometry), eye examination, phoniatric examination and logopedic evaluation (aimed at evaluating chewing/swallowing)

Registry
clinicaltrials.gov
Start Date
September 15, 2022
End Date
December 30, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
IRCCS Eugenio Medea
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

cognitive evaluation by Raven Matrices

Time Frame: through study completion,an average of 2 years

Raven Matrices , Z scores=/\> 0,00 (in range); Z scores =/\< -2,00 (deficiency)

cognitive evaluation by Continous Performance Test 3

Time Frame: through study completion,an average of 2 years

Continous Performance Test 3: T mean Scores 50 SD 10 (SD: standard deviation) (T=45-59 in range; T =/\>60 below range)

cognitive evaluation by Rey Figure test

Time Frame: through study completion,an average of 2 years

Rey Figure test: Z scores=/\> 0,00 (in range); Z scores =/\< -2,00 (deficiency):

cognitive evaluation by Digit Span and CORSI Test

Time Frame: through study completion,an average of 2 years

Digit Span and CORSI Test:Z scores=/\> 0,00 (in range); Z scores =/\< -2,00 (deficiency)

cognitive evaluation by Wechsler Intelligence scale

Time Frame: through study completion,an average of 2 years

Wechsler Intelligence scale: mean score 100 SD 15 (SD: Standard Deviation):deficiency when 2 Standard Deviation below average)

Motor function evaluation by Muscular Impairment Rating Scale

Time Frame: through study completion,an average of 2 years

Muscular Impairment Rating Scale (MIRS) in assessing patients with myotonic dystrophy type 1 (DM1). The MIRS is a ordinal five-point rating scale, where grade 1 = no clinical muscular impairment; grade 2 = early muscular impairment (clinical myotonia, facial weakness, and weakness of neck flexors) without limb weakness; grade 3 = distal weakness; grade 4 = mild to moderate (3 ≤ core \< 5) proximal weakness; grade 5 = severe (MRC score\<3)proximal weakness proximal weakness

cognitive evaluation by Trail Making Test A-B

Time Frame: through study completion,an average of 2 years

Trail Making Test A-B: Z scores=/\> 0,00 (in range); Z scores =/\< -2,00 (deficiency)

Secondary Outcomes

  • clinical evaluation by Epworth Sleepiness Scale(through study completion,an average of 2 years)
  • cognitive evaluation by Wisconsin Card Sorting Test(through study completion,an average of 2 years)
  • cognitive evaluation by Tower of London test(through study completion,an average of 2 years)
  • cognitive and behavioral evaluation by Vineland Adaptive Behavior Scales(through study completion :an average of 2 years)
  • cognitive and behavioral evaluation by Minnesota Multiphasic Personality Inventory(through study completion,an average of 2 years)

Study Sites (1)

Loading locations...

Similar Trials